Using oncolytic viruses to enhance CAR T cell therapy for solid tumors
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
This study is looking at how using special viruses with CAR T cell therapy might help make the treatment work better for people with solid tumors by helping the CAR T cells find and attack the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10992143 on NIH RePORTER |
What this research studies
This research investigates how oncolytic viruses can be used to improve the effectiveness of CAR T cell therapy in treating solid tumors. The approach involves loading these viruses onto CAR T cells before they are administered to patients, which may help the CAR T cells to better target and attack tumor cells. By creating a more inflammatory tumor microenvironment, the therapy aims to enhance the recruitment and functionality of CAR T cells within the tumor. The research is based on promising preclinical results showing improved tumor responses in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded well to conventional therapies.
Not a fit: Patients with hematological malignancies or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown that combining oncolytic virotherapy with immunotherapies can enhance anti-tumor responses, suggesting a promising avenue for this approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Vile, Richard G. — Mayo Clinic Rochester
- Study coordinator: Vile, Richard G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.